About: Mission

There is a complex array of molecules released during upper intestinal enzymatic digestion and colonic microbial metabolism of foods, health promoting supplements and harmful food contaminants. These molecules derived after digestion generally differ greatly in their structure, bioavailability and bioactivity from the original food components and are largely responsible for the health benefits or risks to the host. 

Our lab’s overarching aim is characterizing the bioactives that appear during digestive processes and identify the molecules that are absorbed to affect host metabolic activities. We are particularly focused on inflammation and oxidative stress that play key roles in the development of a wide variety of metabolic disorders. 

To identify the bioactives after digestion, we utilize a variety of methodological innovations including our proprietary benchtop computer-controlled gut digestion model. Several important results have been generated using this model, including identification of anti-cancer microbial metabolites from anthocyanin-rich sweet potato and potato cultivars. This highly innovative platform has attracted national and international attention for the setup of this system in biomedical and nutritional research laboratories (Queensland U, U Eastern Finland). 


Our ongoing research uses the gut digestion model in combination with intestinal and hepatic cell culture models as well as other cell culture systems to identify health promoting post-absorptive bioactives using meta‐omics including metabolomics and proteomics. This work is currently focused on the promising benefits of supplements (polyphenols, probiotics, collagen hydrolysates) towards osteoarthritis, osteoporosis and autism spectrum disorder. These studies are also complemented with experimentation using advanced animal models. We are developing an integrative analysis of multi-“omic” molecular profiling to gain a mechanistic understanding of the cellular and functional characterizations that will provide a ground foundation to support clinical intervention trials. 

Exposure to such xenobiotics (i.e., foreign chemicals not occurring naturally in the environment of living organisms) can lead to diminished abundance and diversity of the gut microbiome. Such microbiome disturbances are associated with disorders and diseases in the host. A major direction of our research is to study how the human microbiome is harmed by exposure to deleterious food and water components (polychlorinated biphenyls (PCBs), nanoparticles used as food additives and packaging, antibiotic resistance gene transfer agents). We are identifying key microbiome biomarkers triggered by such exposures that can be associated with pathophysiological outcomes. An exciting research direction is that we are identifying probiotics, prebiotics and polyphenols that can protect against and rescue against the harm caused by xenobiotics to the human gut microbiome.

Collaborations

Universities and Research Institutions 

  • Institut National de la Recherche Scientifique

  • Johannes Kepler University Linz

  • Kuwait University 

  • Laval University

  • McGill Genome Centre

  • Université du Quebec à Montréal

  • University of Alberta

  • University of Eastern Finland

  • University of Hong Kong

  • University of Queensland


Collaborating Researchers


Government Institutions

  • Health Canada

Companies